We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Innovative Smartphone and AI-Based Tests Featured at AACC 2022

By LabMedica International staff writers
Posted on 27 Jul 2022
Print article
Image: Smartphone and AI-based tests could resolve challenges in laboratory testing (Photo courtesy of Pexels)
Image: Smartphone and AI-based tests could resolve challenges in laboratory testing (Photo courtesy of Pexels)

Scientists have developed a cheap, convenient smartphone test for monitoring patients at risk for dangerous blood clots. Research demonstrating that this test works, along with a second study on using artificial intelligence (AI) to improve testing and treatment for people with kidney stones, will be presented at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo. Both studies could help resolve longstanding challenges in healthcare and laboratory testing.

Test with Smartphone App May Predict Blood Clot Risk

People who take the blood-thinning medication warfarin to prevent blood clots - which can lead to heart attacks - need frequent blood testing to ensure that the drug is working. Currently, this testing occurs in a clinical laboratory or with expensive at-home testing systems. It involves a particular measure of the time it takes for a clot to form, called prothrombin time (PT), and calculating the international normalized ratio (INR) so doctors can compare results between different tests or laboratories.

A team of researchers from the University of Washington (Seattle, WA, USA) developed a test that quickly and inexpensively determines PT/INR using a smartphone. The test uses a smartphone's built-in vibration motor and camera to track movement of a copper particle in a drop of blood. To see whether the test works, the researchers tested blood from 140 anonymous patients. The team also tested blood from 79 patients with known blood-clotting issues. In both groups, the new test produced results similar to laboratory PT/INR tests. As a next step, the researchers are planning to research whether patients can use the new test by themselves at home. The envision it being helpful for people in rural areas, to minimize long and increasingly expensive trips to doctors. The team hopes the test will lead to more people spending more time in the desirable PT/INR range, which would mean they are not at risk for clots or (on the flipside) for uncontrolled bleeding.

"The goal is to decrease complications while making PT/INR testing more convenient and less expensive," said Kelly Michaelsen, MD, PhD, who led the team.

Improving Kidney Stone Analysis and Treatment

Kidney stones are common, affecting more than 1 in 10 people. If left untreated, these hard deposits made of minerals and salts can lead to severe pain, urinary tract infections, and loss of kidney function. Effective treatment and prevention rely on knowing what stones are made of, which is often determined through a manual process using Fourier transform infrared spectroscopy (FTIR). However, mistakes in FTIR interpretation and reporting can lead to inappropriate treatments and undermine efforts to prevent future kidney stones through medication, diet, and lifestyle changes.

To improve diagnosis and better guide treatment, researchers at Mayo Clinic (Rochester, MN, USA) created a group of AI-trained algorithms that analyze FTIR kidney stone composition results. The researchers then conducted a study to determine whether the algorithms could find errors in kidney stone composition results that had been reviewed and reported by a clinical laboratory technologist. Within the 12-month study period, these AI-trained algorithms reviewed manual analyses of 81,517 kidney stones. While the technologist's and AI's interpretations agreed 90% of the time, the researchers determined that manual entry errors and/or incorrect technologist interpretations before use of AI occurred at a rate nearly eight times higher than after the start of AI use.

"Clinical laboratories continuously adopt technology to improve the accuracy of lab tests. By adopting AI, clinical laboratories can reduce errors in results sent to physicians. This study is an example of how the fields of laboratory medicine, data science, information technology, and biostatistics can work together to improve patient care," said Patrick Day, MPH, MLS (ASCP), who led the team.

Related Links:
University of Washington 
Mayo Clinic 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more